Calamos Advisors LLC Has $13.92 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Calamos Advisors LLC reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 182,573 shares of the medical research company’s stock after selling 3,080 shares during the quarter. Calamos Advisors LLC’s holdings in Edwards Lifesciences were worth $13,921,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Advisors Asset Management Inc. boosted its holdings in shares of Edwards Lifesciences by 0.3% during the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after acquiring an additional 117 shares in the last quarter. Apollon Wealth Management LLC increased its position in Edwards Lifesciences by 1.0% in the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after acquiring an additional 119 shares during the period. Geller Advisors LLC raised its stake in shares of Edwards Lifesciences by 6.5% during the first quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after acquiring an additional 120 shares during the last quarter. Legacy Wealth Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after purchasing an additional 134 shares during the period. Finally, KCM Investment Advisors LLC grew its stake in shares of Edwards Lifesciences by 2.7% in the first quarter. KCM Investment Advisors LLC now owns 5,392 shares of the medical research company’s stock worth $635,000 after purchasing an additional 142 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.06 during mid-day trading on Friday, hitting $86.39. The company had a trading volume of 404,510 shares, compared to its average volume of 3,818,674. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The stock’s 50-day moving average price is $90.14 and its 200-day moving average price is $78.19. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $52.00 billion, a price-to-earnings ratio of 37.59, a P/E/G ratio of 4.32 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Edwards Lifesciences’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.64 earnings per share. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Insider Buying and Selling

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the transaction, the vice president now owns 39,503 shares in the company, valued at $3,390,542.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the sale, the vice president now directly owns 173,849 shares in the company, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock worth $17,166,254 in the last quarter. 1.29% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent analyst reports. Citigroup boosted their price target on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Evercore ISI raised their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Truist Financial increased their price target on Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, December 22nd. Morgan Stanley upped their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Finally, Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Monday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.